Xanthohumol as an Adjuvant Therapy in Critically Ill COVID-19 Patients

Summary

It has been well documented that coronavirus COVID-19 disease is associated with massive inflammatory response and cytokine storm. Several medications have been used to ameliorate COVID-19-related inflammation. Xanthohumol, a natural medication extracted from hop cones, possesses strong anti-inflammatory properties and can reduce the severity of inflammatory response. The aim of this study is to analyze the effect of Xanthohumol on clinical course, inflammatory response and outcome in patients admitted to the ICU due to COVID-related acute respiratory failure with an oxygenation index (PaO2/FiO2) less than 150.

Timeline

Start

2020-10-01

Primary completion

2022-01-30

Completion

2025-12-31

Outcome

Outcome not reported

Stopped: “We are waiting for the additional founds.”

Drugs

Indications